Owkin

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Role of institution in the project

Owkin is involved in WP5, WP6, WP7 and WP8.

Owkin will participate in developing the criteria and tools for assessing data quality, in the process of data harmonisation, data de-identification, image annotation and FAIRification.

Owkin will help the integration & adaptation of Substra Federated learning framework.

Owkin will focus on federated approaches and provide technical advisory on those federated approaches for proposed use cases for platform expansion and validation.

Finally, Owkin will provide advisory & consultation on business model for the EUCAIM platform.